Adagene (FRA:978) ROCE %: -18.70% (As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.32
GF Value €11.04
! 5 Warning Signs
View Full Analysis

What is Adagene ROCE %?

Adagene FRA:978 +3.11% 42 ROCE % is -18.70% as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.04. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Adagene's annualized ROCE % for the quarter that ended in Dec. 2025 was -18.70%.

Adagene  (FRA:978) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Adagene ROCE % Related Terms

Adagene ROCE % Historical Data

* Premium members only.

The historical data trend for Adagene's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene ROCE % Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -63.79 -63.81 -17.51 -49.38 -31.65

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.94 -45.92 -57.86 -55.83 -18.70
FRA:978
42GF Score
Adagene Inc FRA:978
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene ROCE % Calculation

Adagene's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-14.897/( ( (85.251 - 36.467) + (66.837 - 21.497) )/ 2 )
=-14.897/( (48.784+45.34)/ 2 )
=-14.897/47.062
=-31.65 %

Adagene's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-7.32/( ( (57.67 - 24.723) + (66.837 - 21.497) )/ 2 )
=-7.32/( ( 32.947 + 45.34 )/ 2 )
=-7.32/39.1435
=-18.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -18.70% mean?
Adagene (FRA:978) has a ROCE % of -18.70% as of Dec. 2025.
Is Adagene's ROCE % too high?
Adagene's current ROCE % is -18.70%. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's ROCE % compare to CNTX and TARA?
Adagene's ROCE % of -18.70% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Adagene's current ROCE % is -18.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current ROCE % of -18.70%. The stock's GF Value™ is €11.04, compared to a current price of €3.32 — trading 69.9% below its estimated fair value. The current ROCE % is -18.70%. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Adagene (FRA:978), the current ROCE % is -18.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.32 is trading 69.9% below its estimated GF Value™ of €11.04.

Key valuation signals for FRA:978:

  • ROCE %: -18.70%
  • GF Value™: €11.04 vs. price of €3.32 (69.9% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price
€11.04
GF Value